Possible role of IL‐23 inhibitor in autoimmune hemolytic anemia

• DOI: 10.1111/ejh.14020
• Publication Date: 2023-06-07T15:18:37Z
• Authors: Naveen Premnath; Urvashi Pandey; Mohak Pandey; K. Venuprasad
• Keywords: Refractory (planetary science)

Rituximab and prednisone are commonly used treatments for autoimmune hemolytic anemia (AIHA), where the body's immune system attacks destroys its red blood cells. However, some AIHA patients may become refractory to rituximab treatment, this can result in continued hemolysis persistent anemia, making it challenging affected individuals manage their symptoms. The underlying causes of refractoriness be complex vary from patient patient. Herein, we present a case newly diagnosed warm cold that remained remission with an interleukin-23 inhibitor.